<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038868</url>
  </required_header>
  <id_info>
    <org_study_id>4901-CL-0201</org_study_id>
    <nct_id>NCT02038868</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of ASP4901 with placebo in patients with
      benign prostatic hyperplasia. The safety and tolerability of ASP4901 will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, parallel-group, placebo-controlled, active-referenced,
      double-blind study. After obtaining the written consent, patients meeting the eligibility
      criteria at the preliminary enrollment will receive oral administration of placebo in a
      single-blinded manner (single-blind placebo run-in period). Then, patients meeting the
      eligibility criteria at the main enrollment will receive drug or placebo (double-blind
      treatment period) for 4 weeks. Furthermore, patients will be followed up for 1 week to
      confirm the safety of the study drugs after the treatment period (safety follow-up period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total IPSS (International Prostate Symptom Score)</measure>
    <time_frame>baseline and at the final evaluation (up to 5 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in each symptom score of IPSS</measure>
    <time_frame>baseline and at the final evaluation (up to 5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IPSS QOL (quality of life) score</measure>
    <time_frame>baseline and at the final evaluation (up to 5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of IPSS responder</measure>
    <time_frame>baseline and at the final evaluation (up to 5 weeks)</time_frame>
    <description>&quot;IPSS responder&quot; is defined as 25% improvement in IPSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of ASP4901</measure>
    <time_frame>up to 5 weeks</time_frame>
    <description>only for ASP4901 group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>ASP4901 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP4901</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP4901 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>oral</description>
    <arm_group_label>Tamsulosin group</arm_group_label>
    <other_name>YM617</other_name>
    <other_name>Harnal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dysuria associated with BPH for at least 12 weeks before providing consent

          -  a total IPSS core of 13 or higher

          -  a QOL score of 3 or higher

          -  a maximum urinary flow rate (Qmax) of ≥4 mL/sec and &lt;15 mL/sec.

          -  a prostate volume of ≥20 mL.

        Exclusion Criteria:

          -  A postvoid residual volume (PVR) of &gt;350 mL

          -  A previous or concurrent symptomatic urinary tract infection within 4 weeks of the
             study

          -  A cataract operation scheduled to be performed during the study period

          -  Previous or concurrent clinically relevant cardiovascular or cerebrovascular disorder
             within 24 weeks prior to the study

          -  Hypersensitivity to ASP4901 or tamsulosin hydrochloride

          -  Presence of serious hepatic diseases, renal diseases, immunological diseases, or
             pulmonary diseases that are clinically relevant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>ASP4901</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

